Xeris Biopharma Holdings, Inc. Cash Flow Statement
XERS / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Xeris Biopharma Holdings, Inc. generated $29M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | $554.0K | -$54.8M | -$62.3M | -$122.7M | -$122.7M | -$91.1M |
| Depreciation & Amortization | $1.3M | $1.2M | $1.5M | $1.3M | $1.3M | $1.5M |
| Operating Cash Flow | $28.6M | -$37.0M | -$47.0M | -$95.5M | -$95.5M | -$80.6M |
| Capital Expenditures | - | - | - | - | $1.1M | $377.0K |
| Free Cash Flow | - | - | - | - | -$96.6M | -$80.9M |
| FCF Margin | - | - | - | - | -194.8% | - |